Hoe CRISPR de genêskunde flugger omskriuwt as regeljouwers folgje kinne
May 28, 2026 · Frisian News
Gene-editing company CRISPR Therapeutics has won approval for three treatments in two years, while regulatory agencies struggle to keep pace with the science. The speed raises questions about safety oversight and who decides which diseases deserve a cure.
FryskYn maart 2026 makke CRISPR Therapeutics de FDA-goedkarring bekend foar syn tredde geneditearjende terapy yn 24 moannen. Elk medisyn rjochtet him op in seldsume bloedsteurnis en kostet tusken 400.000 en 600.000 dollar per pasjint. It bedriuw wurdt no wurdearre op hast 30 miljard dollar, foaral boud op de belofte dat CRISPR genetyske sykten oan de woartel genêze kin. Mar de fluchheid fan goedkarring ropt in drege fraach op: kin de FDA wier folgje wat der bart neidat pasjinten de klinyk ferlitten hawwe?
Regelsjouwers yn Amearika en Jeropa karden dizze terapyen goed op basis fan gegevens út fase 2-ûndersiken, net de gruttere fase 3-stúdzjes dy't gewoanlik de feilichheidsgegevens fan in medisyn fêstlizze. De FDA komprimearre beoardielingstidlinen ta minder as seis moannen per oanfraach. In amtner yn Brussel fertelde ferline jier oan de Financial Times dat har team net oer de technyske ekspertize beskikt om CRISPR syn genetyske sequencing folslein te kontrolearjen. In oare regeljouwer joech ta dat it agentskip in terapy goedkard hie sûnder alle mooglike off-target effekten te begripen, de sneden dy't de genetyske skjirre op de ferkearde plakken yn it genoom makket.
CRISPR Therapeutics bestege tusken 2020 en 2025 4,2 miljoen dollar oan lobbying yn de Feriene Steaten, neffens federale publikaasjegegevens. It bedriuw sette eardere FDA-personiel yn tsjinst en brûkte harren by gearkomsten mei hjoeddeiske regeljouwers. Dit is net ûnwettich, mar it ropt in foar de hân lizzend punt op: de minsken dy't de regels skriuwe, ferlitte de regearing faak en wurkje foar de bedriuwen dy't se eartiids kontrolearren. De oantrún om rap te gean rint nei ûnderen. As in bedriuw foar pasjinten stiet mei seldsume sykten sûnder oare opsjes, fiele regeljouwers druk om earst ja te sizzen en dernei te sjen.
De goedkarringen litte ek in nauer probleem sjen. CRISPR Therapeutics rjochtet him op sikkelselanemie en bèta-thalassemie, beide faker foarkommend by Afrikaanske en Mediterrane befolkingsgroepen. Dochs skreaun de ûndersiken benammen wite pasjinten yn út rike lannen. In dokter yn Lagos, Nigerje lei in ûndersiker út dat syn sikehûs net oan ûndersiken dielnimme koe omdat it bedriuw gjin betellingen bea foar lokale ûndersiksinfrastruktuer. CRISPR syn genêsmiddels berikke de riken. De earmen krije it parseberjocht.
Yntusken binne off-target effekten al by echte pasjinten opdûkt. Ien gefal, beskreaun yn in medisynsk tydskrift dit jier, behelle ûnferwachte DNA-skea yn in sellijn bûten it doelgen. De pasjint oerlibde, mar it foarfal bewiisde wat skeptisy warskôgen: regeljouwers karden de terapy goed sûnder folsleine kennis fan wat it docht. De FDA kin de fluchheid fan de wittenskip net folgje omdat de wittenskip flugger beweecht as amtners lêze kinne. Dy kleau sil allinnich grutter wurde.
In March 2026, CRISPR Therapeutics announced the FDA approval of its third gene-editing therapy in 24 months. Each treatment targets a rare blood disorder and costs between 400,000 and 600,000 dollars per patient. The company now trades at a market value near 30 billion dollars, built largely on the promise that CRISPR can fix genetic diseases at their root. But the speed of approval raises a hard question: can the FDA actually track what happens after patients leave the clinic?
Regulatory agencies in America and Europe approved these therapies based on data from Phase 2 trials, not the larger Phase 3 studies that typically anchor a drug's safety record. The FDA compressed review timelines to less than six months per application. One official in Brussels told the Financial Times last year that her team lacked the technical expertise to fully audit CRISPR's genetic sequencing data. Another regulator admitted the agency had approved a therapy without understanding all possible off-target effects, the cuts that the genetic scissors make in the wrong places of the genome.
CRISPR Therapeutics spent 4.2 million dollars on lobbying in the United States between 2020 and 2025, according to federal disclosure records. The company employed former FDA staffers and deployed them to meetings with current regulators. This is not illegal, but it raises an obvious point: the people who write the rules often leave government and work for the companies they once watched. The incentive to move fast flows downhill. When a company faces rare-disease patients with no other options, regulators feel pressure to say yes first and watch second.
The approvals also reveal a narrower problem. CRISPR Therapeutics targets sickle cell disease and beta thalassemia, both more common in African and Mediterranean populations. Yet the trials enrolled mostly white patients in wealthy countries. A doctor in Lagos, Nigeria explained to a researcher that his hospital could not participate in trials because the company offered no payment for local research infrastructure. CRISPR's cures reach the rich. The poor get the press release.
Meanwhile, off-target effects have already shown up in real patients. One case, described in a medical journal this year, involved unexpected DNA damage in a cell line outside the target gene. The patient survived, but the incident proved what skeptics warned: regulators approved the therapy without full knowledge of what it does. The FDA cannot follow the speed of the science because the science moves faster than bureaucrats can read. That gap will only widen.
Published May 28, 2026 · Frisian News · Ljouwert, Fryslân